"MIATA"-minimal information about T cell assays

Immunity. 2009 Oct 16;31(4):527-8. doi: 10.1016/j.immuni.2009.09.007.


Immunotherapy, especially therapeutic vaccination, has a great deal of potential in the treatment of cancer and certain infectious diseases such as HIV (Allison et al., 2006; Fauci et al., 2008; Feldmann and Steinman, 2005). Numerous vaccine candidates have been tested in patients with a variety of tumor types and chronic viral diseases. Often, the best way to assess the clinical potential of these vaccines is to monitor the induced T cell response, and yet there are currently no standards for reporting these results. This letter is an effort to address this problem.

Publication types

  • Letter

MeSH terms

  • Cancer Vaccines / immunology
  • Cancer Vaccines / therapeutic use*
  • Humans
  • Immunoassay / standards*
  • Immunotherapy
  • Monitoring, Immunologic / standards*
  • Neoplasms / therapy*
  • Practice Guidelines as Topic / standards*
  • T-Lymphocytes / immunology*
  • Viral Vaccines / immunology
  • Viral Vaccines / therapeutic use*
  • Virus Diseases / therapy*


  • Cancer Vaccines
  • Viral Vaccines